NDA 022201 · Ferring
Firmagon
Degarelix Acetate · Subcutaneous
NovelLast checked: Nov 19, 2026Latest source record: Feb 24, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Dec 24, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
146
40 Phase 3, 22 recruiting
FAERS reports
5,333
3,533 serious, 659 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 30, 2024.
FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer. FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer. ( 1 )
Mechanism: Degarelix is a GnRH receptor antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- FIRMAGON · DEGARELIX ACETATE EQ 120MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
- FIRMAGON · DEGARELIX ACETATE EQ 80MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Degarelix" as an intervention, any sponsor and status, largest first.
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT04513717 · 2,753 participants · Start Jan 21, 2021 · Primary completion Dec 31, 2033
Drug: Apalutamide; Bicalutamide and 8 more · For: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
Sites: Fairbanks, Alaska; Gilbert, Arizona; Peoria, Arizona · 602 sites in all
- Prostate Adenocarcinoma TransCutaneous HormonesPivotal-lookingStatus unknown
University College, LondonAcademic, hospital or other
NCT00303784 · 2,200 participants (planned) · Start Mar 2006 · Primary completion Aug 2021
Drug: Goserelin; Estradiol · For: Anemia; Cardiovascular Complications; Hot Flashes and 2 more
Sites: Burton-on-Trent, United Kingdom; Cambridge, United Kingdom; Coventry, United Kingdom · 32 sites in all
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT05050084 · 2,050 participants (planned) · Start Dec 6, 2021 · Primary completion Nov 11, 2026
Drug: Bicalutamide; Buserelin and 8 more · For: Prostate Adenocarcinoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Peoria, Arizona · 576 sites in all
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate CancerPivotal-lookingCompleted
Radiation Therapy Oncology GroupResearch network
NCT00936390 · 1,538 participants · Start Sep 2009 · Primary completion Oct 3, 2020
Drug: bicalutamide; flutamide and 1 more · For: Prostate Cancer
Sites: Birmingham, Alabama; Fairbanks, Alaska; Peoria, Arizona · 518 sites in all
- Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT07751133 · 1,500 participants (planned) · Start Aug 28, 2026 · Primary completion Aug 1, 2029
Drug: Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy · For: Prostate Cancer; mHSPC; mCRPC
Sites: Huddersfield, United Kingdom; Manchester, United Kingdom; Sutton, United Kingdom · 4 sites in all
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT03678025 · 1,273 participants (planned) · Start Sep 24, 2018 · Primary completion Apr 1, 2033
Drug: Abiraterone; Bicalutamide and 9 more · For: Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8 and 2 more
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 338 sites in all
- Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate CancerPivotal-lookingActive, not recruiting
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT02799706 · 885 participants (planned) · Start Sep 25, 2017 · Primary completion Aug 23, 2023
Drug: Degarelix; approved GnRH agonist · For: Prostate Cancer
Sites: Brussels, Belgium; Haine-Saint-Paul, Belgium; Kortrijk, Belgium · 39 sites in all
- A Trial of Degarelix in Patients With Prostate CancerPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00946920 · 859 participants · Start Jun 2009 · Primary completion Mar 2011
Drug: Degarelix; Goserelin acetate · For: Prostate Cancer
Sites: Homewood, Alabama; Little Rock, Arkansas; Fresno, California · 126 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue412
- injection site pain367
- hot flush329
- injection site erythema293
- death227
- asthenia224
- injection site swelling212
- product storage error209
- disease progression174
- pyrexia171
- prostatic specific antigen increased166
- fall162
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 2 |
| 2009 | 34 |
| 2010 | 79 |
| 2011 | 112 |
| 2012 | 104 |
| 2013 | 140 |
| 2014 | 243 |
| 2015 | 194 |
| 2016 | 332 |
| 2017 | 353 |
| 2018 | 367 |
| 2019 | 350 |
| 2020 | 297 |
| 2021 | 406 |
| 2022 | 479 |
| 2023 | 449 |
| 2024 | 489 |
| 2025 | 571 |
| 2026 | 332 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Firmagon (Degarelix Acetate)
2024 spending
$1.2M
Beneficiaries
436
2,082 claims
Per beneficiary
$2,718
$501.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,051,561 |
| 2021 | $1,225,664 |
| 2022 | $1,054,915 |
| 2023 | $1,180,364 |
| 2024 | $1,185,179 |
Part B: Firmagon (Degarelix Acetate) · HCPCS J9155
2024 spending
$17.0M
Beneficiaries
10,573
36,140 claims
Per beneficiary
$1,604
2024 ASP limit $4.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,797,083 |
| 2021 | $18,178,465 |
| 2022 | $18,550,711 |
| 2023 | $18,164,271 |
| 2024 | $16,959,006 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G, Tosco L, Baldewijns M, et al. · Eur Urol 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L, Boccon-Gibod L, Shore ND, et al. · BJU Int 2008 · Clinical Trial, Phase III, Comparative Study
- Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Lopes RD, Higano CS, Slovin SF, et al. · Circulation 2021 · Multicenter Study, Randomized Controlled Trial
- Degarelix for treating advanced hormone-sensitive prostate cancer.
Zengerling F, Jakob JJ, Schmidt S, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.
Spratt DE, George DJ, Shore ND, et al. · JAMA Oncol 2024 · Multicenter Study, Randomized Controlled Trial
- A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer.
Sciarra A, Fasulo A, Ciardi A, et al. · Medicine (Baltimore) 2016 · Comparative Study, Meta-Analysis
Sponsor: Ferring
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.